Oseltamivir CAS 196618-13-0 API Active Pharmaceutical Ingredient C16H28N2O4

Product Description

Product Name: Oseltamivir CAS NO: 196618-13-0

Synonyms:

GS 4104; GOP-A-Flu; TaMiflu-Free;

(3R,4R,5S)-5-amino-4-acetylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acid ethyl ester;

ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate;

ethyl (3R,4R,5S)-5-aMino-4-acetaMido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate;

Oseltamivir (free base);

(3R,5S)-ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate;

TaMvir;Osteltamivir;

[14C]-Oseltamivir;

Oseltamivir; TAMIFLU;

(3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester;

(3R,4R,5S)-4-acetylamino-5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester;

Chemical & Physical Properties

Appearance :white powder

Assay : ≥99%

Density:1.08g/cm3

Boiling Point:473.3℃ at 760 mmHg

Flash Point:240℃

Refractive Index:1.502

Oseltamivir phosphate is a neuraminidase inhibitor anti influenza drug which was launched in 1999. Its trade name is Tamiflu (Tamiflu). It was first discovered by Gilead Sciences, then jointly developed with Roche and approved for listing in the US.

Oseltamivir phosphate is the first effective oral neuraminidase inhibitor, which is effective for influenza A and B viruses. After oral administration, oseltamivir is rapidly converted into its active metabolite oseltamivir carboxylic acid by esterase in the liver and intestine. The configuration of oseltamivir carboxylic acid is similar to the transition state of neuraminic acid, and it can competitively bind to the active site of influenza virus neuraminidase (NA). Therefore, it is a strong and highly selective influenza virus NA inhibitor (NAIS), which mainly interferes the virus from being It is released from infected host cells, thus reducing the spread of influenza A or B virus. Therefore, oseltamivir phosphate is a precursor drug. At present, oseltamivir phosphate (Tamiflu) is still recognized as one of the most effective drugs in the treatment of influenza A (H1N1).

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.